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COPD, characterized by airflow limitation, affects 13 million adults in the US.1
Current treatments, including inhaled corticosteroids, bronchodilators, and anticholinergics primarily provide symptomatic relief and appear to have little impact on
natural disease history.2,3 In healthy individuals, inhalation of tumor necrosis factor
alpha (TNF-α) has been shown to increase airway hyper-responsiveness, one of the
key symptoms in COPD.4,5 Further research has shown an excess of proinflammatory
cytokines, specifically TNF-α, in the sputum of patients with COPD.6–9 Thus, it is
theorized that this cytokine, TNF-α, may play a major role in maintaining the inflammatory state from which COPD patients suffer, and treatment with tumor necrosis
factor inhibitors (TNFi) may help reduce airway inflammation.10
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Background: Limited information exists on the impact of tumor necrosis factor inhibition on
COPD exacerbations. This retrospective study characterized this impact among COPD patients
with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi)
and/or non-biologic disease-modifying antirheumatic drugs (DMARDs).
Patients and methods: Adult COPD patients with 1 diagnosis for rheumatoid arthritis
(RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) before or
within 6 months following the index COPD diagnosis were identified from the Truven Health
MarketScan® databases. Patients were required to have a second claim for RA, PsO, PsA, AS,
or DMARD use (biologic or non-biologic) prior to or up to 6 months following the index date.
Incidence of COPD-related hospitalizations and emergency room (ER) visits was evaluated in
relation to treatment with TNFi and/or DMARDs and other potential risk factors.
Results: The study cohort included 40,687 patients (untreated, 37.7%; non-biologic DMARD,
35.4%; TNFi + non-biologic DMARD, 18%; TNFi, 8.8%). The proportion of patients with
a COPD-related hospitalization and the incidence of COPD-related hospitalization (per 100
person-years) were lowest in the TNFi cohort (8.6%; 3.54, 95% confidence interval [CI]:
3.16–3.95) and the TNFi + non-biologic DMARD cohort (8.4%; 2.85, 95% CI: 2.63–3.08).
In multivariate models, treatment with TNFi + non-biologic DMARD reduced the risk of
COPD-related hospitalization or ER visits by 32% relative to non-biologic DMARDs (hazard
ratio: 0.68; 95% CI: 0.61–0.75).
Conclusion: In real-world settings, TNFi monotherapy confers similar risk for COPD-related
hospitalization or ER visits as a non-biologic DMARD. Decreased risk was found among those
treated with both TNFi and a non-biologic DMARD.
Keywords: COPD, TNF inhibitor, exacerbation, incidence, biologic DMARD
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Studies have sought to examine the efficacy of TNFi
in patients with COPD, both directly and indirectly, with
mixed results.10–13 A randomized clinical trial with etanercept failed to demonstrate efficacy in COPD relative to oral
prednisone; however, the study was limited by the short
treatment duration (two doses) and timing of the treatment
(ie, during an acute exacerbation).14 The most compelling
evidence for efficacy of TNFi in COPD stems from a large
observational study of 15,771 patients with rheumatoid
arthritis (RA) and COPD being treated with etanercept
or infliximab.13 Treatment with etanercept was associated
with a significant reduction in the risk of COPD-related
hospitalization (relative risk [RR]: 0.49, 95% confidence
interval [CI]: 0.29–0.82), whereas infliximab did not exhibit
any significant impact. Along with TNF-α, lymphotoxin
alpha (LTα) is a cytokine produced by lymphocytes which
mediates a variety of inflammatory processes. The exact
role of LTα, which etanercept uniquely inhibits among the
available TNF blocking agents in COPD is unknown, but
its expression is upregulated in the sputum and lung tissue
of COPD patients.15
Results of these studies suggest the potential for benefit of
treatment with TNFi among patients with COPD, however,
small sample sizes, short study periods, and analysis of few
TNFi in these studies limit any conclusive findings. Thus,
we sought to take advantage of TNFi use in the treatment
of autoimmune disorders (RA, psoriasis [PsO], psoriatic
arthritis [PsA], and ankylosing spondylitis [AS]) since 2006
where the majority of evaluated products were approved
during the study period. Using administrative claims data,
this study identified patients with one of the above disorders
along with a diagnosis of COPD in order to characterize the
risk of COPD hospitalizations and emergency room (ER)
visits among patients who were exposed to TNFi and/or
non-biologic disease-modifying antirheumatic drugs
(DMARDs).

Patients and methods
Data source
This retrospective study employed the 2006–2013 Truven
Health Analytics MarketScan® Commercial Claims and
Encounters (Commercial) and Medicare Supplemental
(Medicare) databases, which profile the health care experience (inpatient and outpatient) of individuals with employersponsored primary or Medicare supplemental health insurance. These databases contain only deidentified data and
therefore Institutional Review Board approval to conduct
this study was not necessary.
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Patient selection
Adults $18 years old with a primary or secondary diagnosis
for COPD (International Classification of Diseases, Ninth
Revision, Clinical Modification [ICD-9-CM] 490.xx-492.
xx, 496.xx) on a non-diagnostic claim (a service that was
not performed to test for or ‘rule out’ a diagnosis) between
January 1, 2006 and June 30, 2012 were identified (date of
first COPD diagnosis = index date). Additionally, patients
were required to have an inpatient or outpatient claim with a
non-diagnostic diagnosis for RA (ICD-9-CM: 714.0x), PsO
(ICD-9-CM: 696.1x), PsA (ICD-9-CM: 696.0x), or AS (ICD9-CM: 720.0x), and a second claim for RA, PsO, PsA, or AS,
or use of a biologic or non-biologic DMARDs prior to or up
to 6 months following the index date. Treatment of Crohn’s
disease (ICD-9-CM: 555.xx) or ulcerative colitis (ICD-9-CM:
556.xx) can include very different dosing schedules that may
impact study outcomes, thus, patients with a diagnosis of
either in the pre- and post-period were excluded.
Patients were further stratified into four treatment cohorts
based on the use of TNFi or non-biologic DMARDs during the variable-length follow-up period: 1) TNFi only
(adalimumab, certolizumab, etanercept, infliximab, golimumab) cohort; 2) TNFi + non-biologic DMARD (methotrexate, minocycline, sulfasalazine, hydroxychloroquine,
leflunomide, cyclosporine, azathioprine, and gold sodium
thiomalate) cohort; 3) Non-biologic DMARD only cohort;
and 4) Untreated cohort. Treatment cohorts were mutually
exclusive, patient data was only included in one treatment
cohort based upon evidence of TNFi and/or non-biologic
DMARD use during the post-index period.

Study outcomes
The proportion of patients having a COPD-related hospitalization was reported, and the incidence of COPD-related hospitalization per 100 person-years was assessed for each of the
four treatment cohorts. Patients were followed with a fixed
length of 12-month pre-index period and a variable length
post-index period with a minimum of 12 months. Persontime at risk was defined as the time since index date to one
of the following events, whichever occurred first: 1) COPD
hospitalization, 2) inpatient death, 3) the end of enrollment,
or 4) the end of data availability (June 30, 2013). In addition,
a sensitivity analysis to test the robustness of the results was
conducted to evaluate incidence of COPD-related ER visits
or first COPD-related hospitalization. Patients with an ER
visit prior to a COPD hospitalization were followed until
the date of hospitalization for the primary study outcome.
COPD-related hospitalizations were identified by primary
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or secondary diagnosis of COPD on any inpatient claims
during the post-period. If the index COPD diagnosis was on
an inpatient claim, the start of the study outcome evaluation
period was shifted to the day following the discharge date
of the index hospitalization. COPD-related ER visits were
captured by primary or secondary diagnosis of COPD for ER
services resulting in patients being discharged home.

Other variables
Patient demographic characteristics and clinical characteristics, including the Deyo-Charlson Comorbidity Index,
comorbid medical conditions (1 medical claim) and
concomitant medications (1 prescription claim) were
measured at index date and during the 12-month pre-index
period, respectively.

Statistical methods
Proportional hazards regression analyses were performed
to identify factors contributing to the risk of COPDrelated hospitalization or ER use. The explanatory items
included patient treatment cohort (TNFi only, TNFi + nonbiologic therapies, non-biologic DMARD only [reference]),

baseline demographic characteristics, comorbidities and
medication exposure. Analyses were conducted using SAS
9.3 (SAS Institute Inc., Cary, NC, USA).

Results
A total of 40,687 patients met study eligibility criteria and
were included in the analysis. Of these, 15,347 (37.7%) were
not treated with either a TNFi or DMARD, 14,420 (35.4%)
were treated with a non-biologic DMARD only, 7,337
(18.0%) were treated with both a TNFi and a non-biologic
DMARD, and 3,583 (8.8%) received treatment with a TNFi
only (Figure 1) during the post-index follow-up period.
Overall, patients had an average age of 59.8 years
(standard deviation [SD] 13.9 years). The majority were
females (67.3%), covered by a capitated health plan (90.9%),
and resided in the South region of the US (36.6%) (Table 1);
this distribution matches that of the underlying data source.
There were some notable differences among the four treatment cohorts. In particular, the TNFi only cohort was
younger, and had the highest proportion of males (41.8%).
Patients were followed for a mean of 830 days (SD 634 days),
with the longest for the TNFi + non-biologic DMARD cohort
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Figure 1 Patient selection.
Abbreviations: AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; TNFi, tumor
necrosis factor-alpha inhibitor.
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Table 1 Patient demographic characteristics
Demographic
characteristics

All patients

TNFi only

TNFi + DMARD

DMARD only

Untreated

N=40,687

n=3,583

n=7,337

n=14,420

n=15,347

Age (years), mean (SD)
Age group (years), n (%)
18–34
35–44
45–54
55–64
65
Female, n (%)
Geographic region, n (%)
Northeast
North Central
South
West
Unknown
Insurance plan type, n (%)
Capitated
Non-capitated
Days of follow-up, mean (SD)

59.8 (13.9)

55.0 (13.5)

57.3 (12.0)

61.9 (13.1)

60.2 (15.0)

1,720 (4.2)
3,531 (8.7)
8,240 (20.3)
13,329 (32.8)
13,867 (34.1)
27,373 (67.3)

258 (7.2)
497 (13.9)
947 (26.4)
1,094 (30.5)
787 (22.0)
2,087 (58.3)

280 (3.8)
739 (10.1)
1,769 (24.1)
2,702 (36.8)
1,847 (25.2)
5,370 (73.2)

380 (2.6)
914 (6.3)
2,548 (17.7)
4,829 (33.5)
5,749 (39.9)
10,283 (71.3)

802 (5.2)
1,381 (9.0)
2,976 (19.4)
4,704 (30.7)
5,484 (35.7)
9,633 (62.8)

6,280 (15.4)
12,556 (30.9)
14,891 (36.6)
6,588 (16.2)
372 (0.9)

538 (15.0)
1,002 (28.0)
1,419 (39.6)
587 (16.4)
37 (1.0)

950 (13.0)
2,166 (29.5)
2,919 (39.8)
1,243 (16.9)
59 (0.8)

2,080 (14.4)
4,704 (32.6)
5,202 (36.1)
2,323 (16.1)
111 (0.8)

2,712 (17.7)
4,684 (30.5)
5,351 (34.9)
2,435 (15.9)
165 (1.1)

36,967 (90.9)
3,720 (9.1)
882 (614)

3,259 (91.0)
324 (9.0)
888 (591)

6,649 (90.6)
688 (9.4)
1,073 (648)

13,084 (90.7)
1,336 (9.3)
905 (609)

13,975 (91.1)
1,372 (8.9)
767 (580)

Abbreviations: DMARD, disease-modifying antirheumatic drug; SD, standard deviation; TNFi, tumor necrosis factor inhibitors.

(1,073 days, SD 648 days) and the shortest for the untreated
cohort (757 days, SD 580 days) (Table 1).
Patients in the TNFi only cohort had slightly lower
Deyo-Charlson Comorbidity Index scores during the baseline
period. The most prevalent comorbidities included hypertension (45.0%), hyperlipidemia (28.1%), and Type II diabetes
(17.6%) with the highest prevalence seen in the untreated
cohort. Over one-half of the patients had RA during the
baseline with the highest proportion seen in TNFi + nonbiologic DMARD (78.3%) and non-biologic DMARD only
(70.5%) cohorts. Nearly one-in-four patients were diagnosed
with PsO, with the highest in the TNFi only (39.8%) or the
untreated cohort (39.7%). During the 12-month pre-period,
44.3%, 35.5%, and 23.8% of study patients were treated with
oral, intravenous (IV), and inhaled corticosteroids, respectively, and 19.2%, 10.0%, and 2.7% were on short-acting
beta-agonist (SABA), long-acting beta-agonist (LABA),
and long-acting anti-muscarinics, respectively. The use of
these medications increased during the follow-up period.
The TNFi + non-biologic DMARD and the DMARD only
cohorts consistently had higher use of these concomitant
medications than the TNFi only and the untreated cohorts;
the same pattern was observed for pre-period antibiotics
use (Table 2).
The proportion of patients who had a COPD-related
hospitalization during the follow-up period was lower for
the TNFi only (8.6%) and the TNFi + non-biologic DMARD
cohort (8.4%) than that for the non-biologic DMARD only
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(11.7%, both P0.0001) and the untreated cohort (14.2%,
both P0.0001). Figures 2 and 3 display the unadjusted
and adjusted time to first COPD-related hospitalization. The
untreated cohort had the shortest mean time from the index
COPD diagnosis to the first COPD-related hospitalization
(356 days, SD 451 days). Incidence rates of COPD-related
hospitalization per 100 person-years were lowest in the
TNFi + non-biologic DMARD (2.85; 95% CI: 2.63–3.08)
and the TNFi only cohorts (3.54; 95% CI: 3.16–3.95). Similar
patterns were observed in a sensitivity analysis expanding
the study outcome to include either COPD-related ER visit
or first COPD-related hospitalization.
Results from multivariable analysis revealed that use of
TNFi treatment + non-biologic DMARD reduced the risk of
COPD-related hospitalization or ER visits by 32%, relative to
the non-biologic DMARD only patients (hazard ratio [HR]:
0.678; 95% CI: 0.61–0.754). The hazard of hospitalization or
ER visit between the TNFi only cohort and the non-biologic
DMARD only cohort was statistically similar (HR: 1.003; 95%
CI: 0.862–1.167). After adjusting for other covariates including biologic and non-biologic DMARD use, hazard of COPDrelated hospitalization or ER visit were significantly higher in
older patients (aged 45–54, 55–64, and 65 years) as compared with patients aged 18–44 (P0.05 for all). Females had
a lower hazard of hospitalization or ER visit than males (HR:
0.828; 95% CI: 0.767–0.894) (Figure 4). Biologic DMARD
use (adalimumab, infliximab, and etanercept), concomitant
medication use (self-administered corticosteroids, SABA,
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Clinical characteristics
Deyo-Charlson Comorbidity Index, mean (SD)
Baseline comorbid conditions, n (%)
Anxiety
Asthma
Congestive heart failure
Depression
Hyperlipidemia
Hypertension
Obesity
Osteoarthritis
Osteoporosis
Pneumonia
Type 2 diabetes
Pre-index TNFi indicated condition, n (%)
Rheumatoid arthritis
Psoriasis
Psoriatic arthritis
Ankylosing spondylitis
Pre-index concomitant medications, n (%)
Oral/self-administered corticosteroids
IV corticosteroids
Inhaled corticosteroids
SABA
LABA
Long-acting anti-muscarinics
Antibiotics
Theophylline
Ipratropium bromide
Other biologics
Physician specialty at index COPD diagnosis, n (%)
Rheumatologist
Dermatologist
Pulmonologist

All patients

TNFi only

TNFi + DMARD

DMARD only

Untreated

N=40,687

n=3,583

n=7,337

n=14,420

n=15,347

1.5 (1.6)

1.1 (1.4)

1.4 (1.2)

1.7 (1.5)

1.5 (1.8)

2,990 (7.3)
5,209 (12.8)
2,714 (6.7)
4,220 (10.4)
11,423 (28.1)
18,314 (45.0)
2,138 (5.3)
5,992 (14.7)
3,060 (7.5)
1,606 (3.9)
7,179 (17.6)

260 (7.3)
424 (11.8)
137 (3.8)
342 (9.5)
899 (25.1)
1,397 (39.0)
194 (5.4)
441 (12.3)
179 (5.0)
98 (2.7)
594 (16.6)

474 (6.5)
922 (12.6)
260 (3.5)
755 (10.3)
1,658 (22.6)
2,873 (39.2)
320 (4.4)
1,101 (15.0)
576 (7.9)
216 (2.9)
1,069 (14.6)

913 (6.3)
1,963 (13.6)
1,011 (7.0)
1,422 (9.9)
3,938 (27.3)
6,678 (46.3)
671 (4.7)
2,240 (15.5)
1,316 (9.1)
623 (4.3)
2,495 (17.3)

1,343 (8.8)
1,900 (12.4)
1,306 (8.5)
1,701 (11.1)
4,928 (32.1)
7,366 (48.0)
953 (6.2)
2,210 (14.4)
989 (6.4)
669 (4.4)
3,021 (19.7)

23,101 (56.8)
9,633 (23.7)
3,002 (7.4)
1,057 (2.6)

1,514 (42.3)
1,425 (39.8)
675 (18.8)
260 (7.3)

5,747 (78.3)
768 (10.5)
817 (11.1)
172 (2.3)

10,165 (70.5)
1,351 (9.4)
753 (5.2)
158 (1.1)

5,675 (37.0)
6,089 (39.7)
757 (4.9)
467 (3.0)

18,042 (44.3)
14,455 (35.5)
9,693 (23.8)
7,797 (19.2)
4,079 (10.0)
1,092 (2.7)
28,513 (70.1)
211 (0.5)
2,032 (5.0)
113 (0.3)

1,272 (35.5)
1,147 (32.0)
814 (22.7)
664 (18.5)
342 (9.5)
90 (2.5)
2,461 (68.7)
13 (0.4)
142 (4.0)
3 (0.1)

4,049 (55.2)
3,064 (41.8)
1,940 (26.4)
1,513 (20.6)
825 (11.2)
192 (2.6)
5,522 (75.3)
36 (0.5)
343 (4.7)
14 (0.2)

7,776 (53.9)
5,387 (37.4)
3,784 (26.2)
3,059 (21.2)
1,622 (11.2)
455 (3.2)
10,678 (74.1)
88 (0.6)
846 (5.9)
68 (0.5)

4,945 (32.2)
4,857 (31.6)
3,155 (20.6)
2,561 (16.7)
1,290 (8.4)
355 (2.3)
9,852 (64.2)
74 (0.5)
701 (4.6)
28 (0.2)

15,152 (37.2)
11,306 (27.8)
3,521 (8.7)

1,356 (37.8)
1,375 (38.4)
294 (8.2)

3,960 (54.0)
1,464 (20.0)
628 (8.6)

6,589 (45.7)
2,966 (20.6)
1,431 (9.9)

3,247 (21.2)
5,501 (35.8)
1,168 (7.6)

Abbreviations: DMARD, disease-modifying antirheumatic drug; IV, intravenous; LABA, long-acting beta-agonist; SABA, short-acting beta-agonist; SD, standard deviation;
TNFi, tumor necrosis factor inhibitors.

LABA, ipratropium bromide, long-acting anti-muscarinics,
and theophylline), and several comorbidities (anxiety, congestive heart failure, depression, hypertension, obesity, and
osteoporosis) were all significantly associated with increased
risk of COPD-related hospitalization or ER visit (All P0.05)
(Figure 5). Sensitivity analysis conducted among only patients
with a diagnosis of RA were similar to the overall results.
Analysis of an array of clinical and demographic factors
among COPD patients who underwent different treatments
showed that older patients, those with worse general health
and select preexisting comorbid conditions, and pretreatment
with COPD medications (SABAs, LABAs, long-acting antimuscarinics, theophylline, and TNFi) had increasing hazards
for COPD-related hospitalization or ER visits. Stratified
analysis was conducted where four additional Cox models
were fit for patients in age groups 18–44, 45–54, 55–64, and

International Journal of COPD 2017:12

65 years. The findings were consistent with those for the
combined sample. The use of combination TNFi and nonbiologic DMARD therapy was associated with a reduction
in the hazard of COPD-related hospitalization or ER visits
compared to non-biologic DMARD only in all age groups,
though not statistically significant for the youngest age group:
18–44 years (HR: 0.877; 95% CI: 0.561–1.373), 45–54
years (HR: 0.731; 95% CI: 0.563–0.949), 55–64 years (HR:
0.619; 95% CI: 0.513–0.747), and 65 years (HR: 0.700;
95% CI: 0.596–0.823). Similarly, there were no statistically
significant differences between the TNFi only cohort and
the non-biologic DMARD only cohort across all four age
subgroups (Table S1). The combined model also found that
the presence of pre-index period asthma, AS, and PsO were
each associated with lower hazard of COPD-related hospitalization or ER visits during follow-up (Figure 5).
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Figure 2 Unadjusted probability of first COPD-related hospitalization by days after starting treatment.
Abbreviations: TNFi, tumor necrosis factor inhibitors; IP, inpatient.

Discussion
This large retrospective database analysis of 40,687 COPD
patients from a nationally representative health care
administrative database found that patients on treatment
containing TNFi had lower incidence rates of COPD-related
hospitalization than patients treated with non-biologic
DMARDs only or untreated patients. Similar findings were
observed when expanding the study outcome to include both
COPD-related ER visit and hospitalization. After adjusting
for patient baseline demographic and clinical differences,
TNFi + non-biologic DMARD treatment was associated
with a significant reduction in the hazard of COPD-related
hospitalization or ER visits compared to non-biologic
DMARD only; however, there was no significant difference in the hazard of COPD-related hospitalization or ER
visits between patients treated with TNFi only and those
treated with non-biologic DMARD only. TNFi are routinely
combined with non-biologic DMARDs such as methotrexate for additional efficacy though monotherapy is often
employed due to adverse events such as gastrointestinal
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discomfort, hepatic laboratory abnormalities, and hematologic cytopenias.16
In 2008, a large claims-based analysis of RA and COPD
patients treated with etanercept and infliximab reported
significant reduction in the risk of COPD-related hospitalization with the use of TNFi (RR: 0.62; 95% CI: 0.43–0.89)
compared to the untreated, exclusively driven by etanercept
(RR: 0.49; 95% CI: 0.29–0.82).13 However, infliximab did
not have the same effect on risk reduction of hospitalization
(RR: 0.95; 95% CI: 0.59–1.52). Our current analysis was
built upon this approach, with the following differences: more
recent claims data (2006–2013 versus 1995–2004), larger
sample size (40,687 versus 15,771), younger patient sample
(mean age of 60 years versus 67 years), and longer duration
of follow-up (mean 28 months versus 14 months).13 Another
key difference is that our analysis differentiated TNFi monotherapy from TNFi plus concomitant non-biologic DMARD
therapy, whereas Suissa et al13 treated both together. Our
study also examined TNFi as a class and did not evaluate the
outcomes by individual agent. While differential outcomes
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Figure 3 Adjusteda probability of first COPD-related hospitalization by days after starting treatment.
Notes: aAdjusted for age, gender, region, baseline CCI, baseline diagnosis of: RA, PsA, PsO, AS, hypertension, pneumonia, asthma, Type 2 diabetes, obesity, depression,
hyperlipidemia, osteoporosis, congestive heart failure, anxiety, and baseline use of: non-biologic DMARD, oral/self-administered corticosteroids, inhaled corticosteroids,
physician-administered corticosteroids, LABA, SABA, long-acting anti-muscarinics, ipratropium bromide, antibiotics, and baseline biologic use (ETA, ADA, INF, GOL, CTZ,
or other).
Abbreviations: AS, ankylosing spondylitis; CCI, Deyo-Charlson Comorbidity Index; DMARD, disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis;
RA, rheumatoid arthritis; LABA, long-acting beta-agonist; SABA, short-acting beta-agonist; TNFi, tumor necrosis factor inhibitors; IP, inpatient; ETA, etanercept; ADA,
adalimumab; INF, infliximab; GOL, golimumab; CTZ, certolizumab.
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Figure 4 Hazard ratio of COPD-related hospitalization or ER visits during 3-year follow-up period.
Note: Hazard ratios with 95% confidence intervals.
Abbreviations: ER, emergency room; TNFi, tumor necrosis factor inhibitors.

International Journal of COPD 2017:12

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2091

Dovepress

Accortt et al

International Journal of Chronic Obstructive Pulmonary Disease downloaded from https://www.dovepress.com/ by 128.163.8.74 on 07-Mar-2018
For personal use only.

3UHLQGH[ELRORJLFXVH

3UHLQGH[LQKDOHUXVH

$GDOLPXPDE
&HUWROL]XPDE
(WDQHUFHSW
*ROLPXPDE
,QIOL[LPDE
2WKHUELRORJLFV

,QKDOHGFRUWLFRVWHURLGV
,SUDWURSLXPEURPLGH
/RQJDFWLQJDQWLPXVFDULQLFV
/RQJDFWLQJEHWDDJRQLVWV
3UHLQGH[RWKHUPHGLFDWLRQXVH
$QWLELRWLFV
1RQELRORJLF'0$5'V
2UDORUVHOIDGPLQLVWHUHGFRUWLFRVWHURLGV
3K\VLFLDQDGPLQLVWHUHGFRUWLFRVWHURLGV
6KRUWDFWLQJEHWDDJRQLVWV
7KHRSK\OOLQH
3UHLQGH[FRPRUELGFRQGLWLRQV
$QN\ORVLQJVSRQG\OLWLV
$Q[LHW\
$VWKPD
&RQJHVWLYHKHDUWIDLOXUH
'HSUHVVLRQ
+\SHUOLSLGHPLD
+\SHUWHQVLRQ
2EHVLW\
2VWHRDUWKULWLV
2VWHRSRURVLV
3QHXPRQLDZLWKKRVSLWDOL]DWLRQRU,9DQWLELRWLFV
3VRULDVLV
3VRULDWLFDUWKULWLV
5KHXPDWRLGDUWKULWLV
7\SHGLDEHWHV
3UHLQGH[FRPRUELGLW\VFRUH
&KDUOVRQFRPRUELGLW\LQGH[








/RZHUULVNIRU&23'UHODWHG +LJKHUULVNIRU&23'UHODWHG
KRVSLWDOL]DWLRQRU(5YLVLW
KRVSLWDOL]DWLRQRU(5YLVLW
Figure 5 Hazard ratio of COPD-related hospitalization or ER visits during 3-year follow-up period, all ages combined.
Notes: Referent for medication use is no pharmacy claims during pre-index period. Referent for comorbidities is no diagnoses during pre-index period. Referent for
comorbidity score is 0 during pre-index period. Hazard ratios with 95% confidence intervals.
Abbreviations: DMARD, disease-modifying antirheumatic drug; ER, emergency room; IV, intravenous.

for infliximab and etanercept have been reported in the past,
there are no known published studies on newer TNFi such as
certolizumab pegol and golimumab.13 Future analysis at the
drug level is desirable to test the findings from this study.

Limitations
The interpretation of findings from this study should be cautioned with several limitations. Channeling bias may be present
in this analysis and occurs when a high-risk subset of patients
are less likely to be prescribed certain medications than other
low-risk patients. Patients in all cohorts had comparable comorbidity scores and though comorbidities were controlled for in
the adjusted models, the potential for channeling bias remains,
especially if it is related to disease severity or other unobservable
patient characteristics that could influence the study outcomes.
Other limitations stem from using health insurance claims.
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The identification of diagnosis relied on ICD-9 diagnosis codes
which only reflect the claims which physicians submit for
reimbursement. Additionally, past studies have suggested that
COPD severity, timing of treatment (ie, during an acute exacerbation) and subtype of COPD may influence the efficacy of
TNFi in treating COPD.10–12,17 We were unable to capture these
clinical markers using medical claims and thus our findings
warrant further investigation within different subsets of COPD
patients incorporating this clinical data. Finally, this study only
included patients covered by commercial or Medicare insurance, therefore results may not be generalizable to those with
other types of coverage or the uninsured.

Conclusion
This retrospective study of COPD patients with underlying
autoimmune conditions suggests that use of a TNFi alone
International Journal of COPD 2017:12
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confers a similar risk for COPD-related hospitalizations
compared to patients receiving a non-biologic DMARD
alone; however, a decreased risk was apparent among those
treated with both TNFi and a non-biologic DMARD. Multiple
factors were found to be related to COPD hospitalization.
Further analyses are needed to better understand the impact
of disease severity (both COPD and autoimmune disease)
and other factors in the physicians’ decision-making process
as to which patients to treat with TNFi and whether there is a
channeling of patients based on underlying disease profile.
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Supplementary material
Table S1 Adjusted relative risk of a COPD-related IP admission or ER visit by age
Cohort

All ages

TNFi only
TNFi and DMARD
DMARD only

18–44 years

45–54 years

55–64 years

65 years

HR

P-value

HR

P-value

HR

P-value

HR

P-value

HR

P-value

1.003
0.678
1.000

0.97
0.0001
–

0.530
0.877
1.000

0.09
0.57
–

0.999
0.731
1.000

0.99
0.02
–

1.175
0.619
1.000

0.24
0.0001
–

1.002
0.700
1.000

0.99
0.0001
–

Note: ‘–’ indicates referent.
Abbreviations: DMARD, disease-modifying antirheumatic drug; ER, emergency room, HR, hazard ratio; IP, inpatient; TNFi, tumor necrosis factor-alpha inhibitor.
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